ライフサイエンスコーパス: definitive therapy

1 nt reigns, often to the point of withholding definitive therapy.

2 if this association is true for empiric and definitive therapy.

3 (+)) and do not (BCR (-)) have BCR following definitive therapy.

4 ation therapy as the initial and potentially definitive therapy.

5 in vitro and would be particularly useful as definitive therapy.

6 have failed or may serve as a bridge to more definitive therapy.

7 ) or metastases or death (14 articles) after definitive therapy.

8 and transplantation of the liver is the only definitive therapy.

9 tibiotic agents, should they be required for definitive therapy.

10 e and in trying to discern metastasis before definitive therapy.

11 cholecystectomy should be considered as the definitive therapy.

12 ich may decrease the morbidity of subsequent definitive therapy.

13 n of mature new bone appeared to be the only definitive therapy.

14 Two patients died without an attempt at definitive therapy.

15 l was 76% of 99 patients who received TUR as definitive therapy (57% with bladder preserved) compared

16 fidence interval [CI], .29-4.40; P = .84) or definitive therapy (adjusted HR, 0.76; 95% CI, .28-2.07;

17 2 to 0.84; P < .001), more likely to receive definitive therapy (adjusted OR, 1.53; 95% CI, 1.51 to 1

18 in whom carefully performed FSS may serve as definitive therapy and in whom adjuvant RT may not be ne

19 tus and stage at presentation, employment of definitive therapy, and all-cause mortality was assessed

20 surveillance and definition of a trigger for definitive therapy, and prognostication of time to hormo

21 od loss has been controlled but before other definitive therapies are available.

22 Despite significant progress, definitive therapies are often lacking.

23 nces in medical practice have occurred while definitive therapies based on an improved knowledge of d

24 Patients then received definitive therapy based on institutional preferences.

25 beta-lactams are superior to vancomycin for definitive therapy but not for empiric treatment.

26 Immediate delivery is the only definitive therapy, but many maternal complications can

27 : the empirical therapy cohort (ETC) and the definitive therapy cohort (DTC).

28 sfunction were often dissuaded from pursuing definitive therapy, even though most patients died from

29 antation and solid organ transplantation are definitive therapies for several otherwise fatal conditi

30 The role of PCI as definitive therapy for allograft coronary disease (ACD)

31 mediary in cases of treatment failure, or as definitive therapy for benign prostatic hyperplasia and

32 c stem cell transplantation remains the only definitive therapy for LAD; however, the degree of donor

33 ce of prostate carcinoma was suspected after definitive therapy for localized disease, (b) bone scans

34 Lung transplantation is the only definitive therapy for many forms of end-stage lung dise

35 l setting of biochemical failure after prior definitive therapy for primary cancer.

36 n; however, independent of primary location, definitive therapy for teratomas is complete surgical re

37 teremic or having received vancomycin as the definitive therapy for their infections.

38 Liver transplantation represents the only definitive therapy for this disease and has been perform

39 as a bridge to transplantation (BTT), and as definitive therapy for toxic ingestion or idiopathic liv

40 In pursuit of definitive therapy for XLA, we tested ex vivo gene thera

41 infections, beta-lactams are recommended for definitive therapy; however, the comparative effectivene

42 onade in 91 cases (99%) and was the only and definitive therapy in 82% of the cases.

43 Shunting was undertaken as definitive therapy in all.

44 mponade is recommended only as a "bridge" to definitive therapy in patients with cirrhosis and massiv

45 ith corticosteroids and anticonvulsants, and definitive therapy in the form of whole-brain radiation

46 ue obtained by means of biopsy or as part of definitive therapy (including a loop electrosurgical exc

47 bitory concentration </= 8 mug/mL), cefepime definitive therapy is inferior to carbapenem therapy in

48 BCR post definitive therapy is often associated with disease prog

49 cantly in 30%-60% of NSCLC patients for whom definitive therapy is planned.

50 Chemoradiation as definitive therapy is the preferred primary therapy for

51 patient autonomy, and despite the absence of definitive therapy, many newly diagnosed individuals are

52 rgical therapies for recurrent disease after definitive therapy of anal carcinoma, colorectal cancer,

53 beta-lactams with vancomycin for empiric and definitive therapy of MSSA bloodstream infections among

54 es durable tumor control when used either as definitive therapy or as a postoperative adjuvant therap

55 prompt initiation of supportive measures and definitive therapy, outcomes can be improved.

56 e allograft vascular bed, the only currently definitive therapy requires re-transplantation.

57 rior prostatectomy, radiation therapy, or no definitive therapy, respectively).

58 Patients should receive beta-lactams for definitive therapy, specifically antistaphylococcal peni

59 ful strategy to prevent morbidities before a definitive therapy, such as hematopoietic stem-cell tran

60 y, depressed men were less likely to undergo definitive therapy (surgery or radiation) across all ris

61 puted tomographic (CT) technology, and rapid definitive therapy, trauma to the aorta continues to be

62 Definitive therapy was defined as starting treatment bet

63 Patients who received cefepime (n = 17) as definitive therapy were more likely to have a clinical f

64 However, patients who received definitive therapy with a beta-lactam had 35% lower mort

65 tients with ESBL bacteremia who all received definitive therapy with a carbapenem.

66 Physicians might consider definitive therapy with cefazolin for these infections.

67 This study compared definitive therapy with cefazolin vs nafcillin or oxacil

68 blood culture positive for MSSA and received definitive therapy with cefazolin, nafcillin, or oxacill

69 3167 patients, 1163 (37%) patients received definitive therapy with cefazolin.

70 CR) post-therapy will potentially complement definitive therapy with either neo- or adjuvant therapy

71 , improved outcomes have been reported after definitive therapy with hematopoietic stem cell transpla

72 ome women with Graves disease opt to receive definitive therapy with RAI or surgery prior to becoming

73 and nonmetastatic prostate cancer underwent definitive therapy with surgery or radiation therapy wit

74 No recurrences were observed after definitive therapy, with follow-up of 4 +/- 4 years.